Robert Farinotti

9.5k total citations
291 papers, 7.3k citations indexed

About

Robert Farinotti is a scholar working on Oncology, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Robert Farinotti has authored 291 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Oncology, 65 papers in Pharmacology and 46 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Robert Farinotti's work include Drug Transport and Resistance Mechanisms (86 papers), Antibiotics Pharmacokinetics and Efficacy (53 papers) and Pharmacological Effects and Toxicity Studies (40 papers). Robert Farinotti is often cited by papers focused on Drug Transport and Resistance Mechanisms (86 papers), Antibiotics Pharmacokinetics and Efficacy (53 papers) and Pharmacological Effects and Toxicity Studies (40 papers). Robert Farinotti collaborates with scholars based in France, Canada and United States. Robert Farinotti's co-authors include Julie Ducharme, Christine Fernandez, J.P. Haberer, Marion Buyse, François Gimenez, J. M. Desmonts, C Carbon, F. Giménez, Jean-Marie Desmonts and G. Mahuzier and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Gastroenterology.

In The Last Decade

Robert Farinotti

285 papers receiving 7.1k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Robert Farinotti 1.6k 1.4k 1.1k 1.1k 1.1k 291 7.3k
Gerd Mikus 1.4k 0.9× 1.3k 0.9× 1.3k 1.2× 1.5k 1.3× 1.0k 0.9× 254 7.9k
Ron A. A. Mathôt 1.1k 0.7× 1.3k 0.9× 659 0.6× 1.4k 1.3× 1.4k 1.3× 317 8.1k
Caroline M. Perry 878 0.6× 1.2k 0.9× 1.6k 1.4× 599 0.6× 1.5k 1.4× 200 9.1k
Diana Faulds 1.5k 0.9× 785 0.6× 1.2k 1.1× 671 0.6× 2.0k 1.9× 122 10.4k
Robert A. Branch 1.7k 1.1× 1.6k 1.1× 842 0.8× 1.2k 1.1× 1.4k 1.3× 252 9.6k
Évelyne Jacqz-Aigrain 781 0.5× 1.6k 1.1× 871 0.8× 2.9k 2.7× 687 0.6× 307 7.3k
Gillian M. Keating 1.4k 0.9× 1.2k 0.9× 791 0.7× 462 0.4× 2.6k 2.4× 368 12.5k
Lesley J. Scott 1.6k 1.0× 1.4k 1.0× 1.3k 1.2× 551 0.5× 3.1k 2.8× 333 12.9k
Greg L. Plosker 1.2k 0.8× 993 0.7× 996 0.9× 734 0.7× 1.9k 1.8× 261 10.1k
R.C. Heel 808 0.5× 1.7k 1.2× 562 0.5× 688 0.6× 2.1k 1.9× 111 10.9k

Countries citing papers authored by Robert Farinotti

Since Specialization
Citations

This map shows the geographic impact of Robert Farinotti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Farinotti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Farinotti more than expected).

Fields of papers citing papers by Robert Farinotti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Farinotti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Farinotti. The network helps show where Robert Farinotti may publish in the future.

Co-authorship network of co-authors of Robert Farinotti

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Farinotti. A scholar is included among the top collaborators of Robert Farinotti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Farinotti. Robert Farinotti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jovelet, Cécile, Jean Bénard, F Forestier, et al.. (2012). Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin. European Journal of Pharmaceutical Sciences. 46(5). 484–491. 21 indexed citations
3.
Vautier, Sarah, et al.. (2006). ABCB1 (P-glycoprotein) and blood-brain barrier: role in neurological diseases and their treatments. Journal de Pharmacie Clinique. 25(4). 225–235. 1 indexed citations
4.
Jaouen, Annabelle, Agnès Certain, Robert Farinotti, Françoise Brion, & Patrick Arnaud. (2006). Bilan des activités d’information et d’éducation thérapeutique à l’hôpital : application à la description de la place du pharmacien dans une consultation d’observance. Journal de Pharmacie Clinique. 25(3). 160–169. 3 indexed citations
5.
Arrault, Xavier, et al.. (2005). Les synoviorthèses radio-isotopiques : une alternative à l’acide osmique. Journal de Pharmacie Clinique. 24(2). 83–89.
6.
Gil, Sophie, Catherine Julié, Anne Lavergne‐Slove, et al.. (2005). Multidrug Resistance Proteins in Gastrointestinal Stromal Tumors: Site-Dependent Expression and Initial Response to Imatinib. Clinical Cancer Research. 11(21). 7593–7598. 38 indexed citations
7.
Deloménie, Claudine, Nathalie Didier, Albert Faye, et al.. (2005). Increased Expression of MDR1 mRNAs and P-glycoprotein in Placentas from HIV-1 Infected Women. Placenta. 27(6-7). 699–706. 29 indexed citations
8.
Peytavin, Gilles, et al.. (2003). Gestion informatisée des stupéfiants à l'hôpital à l'aide du logiciel Morphée. Journal de Pharmacie Clinique. 21(4). 260–266.
9.
Mahé, E., et al.. (2003). A 6-month prospective survey of cutaneous drug reactions in a hospital setting. British Journal of Dermatology. 149(5). 1018–1022. 202 indexed citations
10.
Rufat, Pierre, et al.. (2002). Information des patients : évaluation de leurs connaissances après prescription de médicaments dans un CHU parisien. Journal de Pharmacie Clinique. 21(2). 115–121. 2 indexed citations
11.
Vatier, J, et al.. (1999). Study of drugs interactions involving diosmectite with an artificial stomach-duodenum model : application to Aids therapeutics. Journal de Pharmacie Clinique. 18(2). 1 indexed citations
12.
Prognon, P., et al.. (1999). Cerium-doped diosmectite for topical application studies of the cerium–clay interaction. International Journal of Pharmaceutics. 181(2). 193–202. 6 indexed citations
13.
Martin‐Chouly, Corinne, et al.. (1998). Chiral chromatographic method to determine the enantiomers of halofantrine and its main chiral desbutyl metabolite in erythrocytes. Journal of Chromatography B Biomedical Sciences and Applications. 712(1-2). 259–262. 8 indexed citations
14.
Giménez, F., et al.. (1996). Uptake of mefloquine enantiomers into uninfected and malaria-infected erythrocytes.. Drug Metabolism and Disposition. 24(6). 689–691. 6 indexed citations
15.
Martin‐Chouly, Corinne, et al.. (1996). Stereoselective pharmacokinetics of mefloquine in young children. European Journal of Clinical Pharmacology. 50(3). 241–244. 17 indexed citations
16.
Fernandez, Christine, et al.. (1993). Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers.. Drug Metabolism and Disposition. 21(6). 1125–1128. 42 indexed citations
17.
Fassoulaki, Argyro, et al.. (1993). Chronic Alcoholism Increases the Induction Dose of Propofol in Humans. Anesthesia & Analgesia. 77(3). 553???556–553???556. 41 indexed citations
18.
Jambou, Ronan, et al.. (1990). L'accès palustre simple en zone de haut niveau de résistance à la chloroquine. I. Evaluation d'un traitement court par la quinine.. Bulletin de la Société de pathologie exotique. 83(1). 46–52. 2 indexed citations
19.
Jambou, Ronan, et al.. (1990). [Uncomplicated attack of malaria in an area with high resistance to chloroquine. I. Evaluation of a short treatment with quinine].. PubMed. 83(1). 46–52. 5 indexed citations
20.
Farinotti, Robert, et al.. (1989). Applications of ferrocene as a label for the liquid chromatography amperometric analysis of some carboxylic amine and carbonyl derivatives. Analusis. 17(10). 559–575. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026